Skip to content

Research at St Andrews

Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments

Research output: Contribution to journalArticle

Author(s)

K. Boswell, H. Cameron, J. West, C. Fleming, S. Ibbotson, R. Dawe, J. Foerster

School/Research organisations

Abstract

Background: Narrowband ultraviolet B (NB-UVB) treatment for psoriasis is considered expensive. However, existing data are based on estimates and do not consider indirect cost savings.

Objectives: To define the actual costs of NB-UVB incurred by the service provider, as well as treatment-associated cost savings.

Methods: We performed data linkage of (i) comprehensive treatment records and (ii) prescribing data for all NB-UVB treatment episodes spanning 6 years in a population of 420 000. We minimized data fluctuation by compiling data from four independent treatment sites, and using drug prescriptions unrelated to psoriasis as a negative control.

Results: National Health Service Tayside spent an average of £257 per NB-UVB treatment course (mean 257 ± 63, range 150–286, across four independent treatment sites), contrasting sharply with the estimate of £1882 used by the U.K. National Institute for Health and Care Excellence. The cost of topical treatments averaged £128 per patient in the 12 months prior to NB-UVB, accounting for 42% of the overall drug costs incurred by these patients. This was reduced by 40% to £53 per patient over the 12-month period following NB-UVB treatment, while psoriasis-unrelated drug prescription remained unchanged, suggesting disease-specific effects of NB-UVB. The data were not due to site-specific factors, as confirmed by highly similar results observed between treatment sites operated by distinct staff. Finally, we detail all staff hours directly and indirectly involved in treatment, allowing direct translation of cost into other healthcare systems.

Conclusions: NB-UVB is a low-cost treatment; cost figures currently used in health technology appraisals are an overestimate based on the data presented here. Creating or extending access to NB-UVB is likely to offer additional savings by delaying or avoiding costly third-line treatments for many patients.
Close

Details

Original languageEnglish
Pages (from-to)1148-1156
Number of pages9
JournalBritish Journal of Dermatology
Volume179
Issue number5
Early online date29 Jul 2018
DOIs
Publication statusPublished - Nov 2018

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy

    Zeltins, A., West, J., Zabel, F., El Turabi, A., Balke, I., Haas, S., Maudrich, M., Storni, F., Engeroff, P., Jennings, G. T., Kotecha, A., Stuart, D. I., Foerster, J. & Bachmann, M. F., 23 Oct 2017, In : npj Vaccines. 2, 13 p., 30.

    Research output: Contribution to journalArticle

  2. Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice

    Foerster, J., Boswell, K., West, J., Cameron, H., Fleming, C., Ibbotson, S. & Dawe, R., 3 Aug 2017, In : PLoS ONE. 12, 8, 14 p., e0181813.

    Research output: Contribution to journalArticle

  3. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

    West, J., Ogston, S., Berg, J., Palmer, C., Fleming, C., Kumar, V. & Foerster, J., Aug 2017, In : Clinical and Experimental Dermatology. 42, 6, p. 651-655 5 p.

    Research output: Contribution to journalArticle

  4. Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability

    West, J., Ogston, S., Palmer, C., Fleming, C., Dawe, R., Kumar, V., Waterston, S. & Foerster, J., Jun 2016, In : British Journal of Dermatology. 174, 6, p. 1407-1410 4 p.

    Research output: Contribution to journalComment/debate

  5. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials

    West, J., Ogston, S. & Foerster, J., 11 May 2016, In : PLoS ONE. 11, 5, 14 p., e0153740.

    Research output: Contribution to journalArticle

Related by journal

  1. Could psoralen plus ultraviolet A1 (“PUVA1”) work? Depth penetration achieved by phototherapy lamps

    Barnard, I. R. M., Eadie, E., McMillan, L., Moseley, H., Brown, T., Wood, K. & Dawe, R., 27 Nov 2019, In : British Journal of Dermatology. Early View, 2 p.

    Research output: Contribution to journalLetter

  2. The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from Atopic Dermatitis patients

    Harkins, C. P., McAleer, M. A., Bennett, D., McHugh, M., Fleury, O. M., Pettigrew, K. A., Oravcová, K., Parkhill, J., Proby, C. M., Dawe, R. S., Geoghegan, J. A., Irvine, A. D. & Holden, M. T. G., 15 Oct 2018, In : British Journal of Dermatology. 179, 4, p. 951-958 8 p.

    Research output: Contribution to journalArticle

  3. Methotrexate in psoriasis under real-world conditions: long-term efficacy and tolerability

    West, J., Ogston, S., Palmer, C., Fleming, C., Dawe, R., Kumar, V., Waterston, S. & Foerster, J., Jun 2016, In : British Journal of Dermatology. 174, 6, p. 1407-1410 4 p.

    Research output: Contribution to journalComment/debate

  4. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer

    Attili, S. K., Lesar, A., McNeill, A., Camacho-Lopez, M., Moseley, H., Ibbotson, S., Samuel, I. D. W. & Ferguson, J., Jul 2009, In : British Journal of Dermatology. 161, 1, p. 170-173 4 p.

    Research output: Contribution to journalArticle

ID: 260534589

Top